Léa Zaffalon

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


11 publications

2024 | 2023 | 2022 | 2021 | 2017 | 2016 |
HSP90β controls NLRP3 autoactivation.
Spel L., Hou C., Theodoropoulou K., Zaffalon L., Wang Z., Bertoni A., Volpi S., Hofer M., Gattorno M., Martinon F., 2024/03. Science advances, 10 (9) pp. eadj6289. Peer-reviewed.
ER-trafficking triggers NRF1 ubiquitination to promote its proteolytic activation.
Chavarria C., Zaffalon L., Ribeiro S.T., Op M., Quadroni M., Iatrou M.S., Chapuis C., Martinon F., 2023/10/20. iScience, 26 (10) p. 107777. Peer-reviewed.
NLRP3 leucine-rich repeats control induced and spontaneous inflammasome activation in cryopyrin-associated periodic syndrome.
Theodoropoulou K., Spel L., Zaffalon L., Delacrétaz M., Hofer M., Martinon F., 2023/01. The Journal of allergy and clinical immunology, 151 (1) pp. 222-232.e9. Peer-reviewed.
CDC42 regulates PYRIN inflammasome assembly.
Spel L., Zaffalon L., Hou C., Nganko N., Chapuis C., Martinon F., 2022/11/15. Cell reports, 41 (7) p. 111636. Peer-reviewed.
The protease DDI2 regulates NRF1 activation in response to cadmium toxicity.
Ribeiro S.T., de Gassart A., Bettigole S., Zaffalon L., Chavarria C., Op M., Nugraha K., Martinon F., 2022/10/21. iScience, 25 (10) p. 105227. Peer-reviewed.
The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.
Op M., Ribeiro S.T., Chavarria C., De Gassart A., Zaffalon L., Martinon F., 2022/05/19. Cell death & disease, 13 (5) p. 475. Peer-reviewed.
Tumor-induced reshuffling of lipid composition on the endoplasmic reticulum membrane sustains macrophage survival and pro-tumorigenic activity.
Di Conza G., Tsai C.H., Gallart-Ayala H., Yu Y.R., Franco F., Zaffalon L., Xie X., Li X., Xiao Z., Raines L.N. et al., 2021/11. Nature immunology, 22 (11) pp. 1403-1415. Peer-reviewed.
Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
Bujisic B., De Gassart A., Tallant R., Demaria O., Zaffalon L., Chelbi S., Gilliet M., Bertoni F., Martinon F., 2017/04/27. Blood, 129 (17) pp. 2420-2428. Peer-reviewed.
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.
De Gassart A., Demaria O., Panes R., Zaffalon L., Ryazanov A.G., Gilliet M., Martinon F., 2016/10. EMBO reports, 17 (10) pp. 1471-1484. Peer-reviewed.
AIM2 inflammasome is activated by pharmacological disruption of nuclear envelope integrity.
Di Micco A., Frera G., Lugrin J., Jamilloux Y., Hsu E.T., Tardivel A., De Gassart A., Zaffalon L., Bujisic B., Siegert S. et al., 2016/08/09. Proceedings of the National Academy of Sciences of the United States of America, 113 (32) pp. E4671-80. Peer-reviewed.
An inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response.
De Gassart A., Bujisic B., Zaffalon L., Decosterd L.A., Di Micco A., Frera G., Tallant R., Martinon F., 2016. Proceedings of the National Academy of Sciences of the United States of America, 113 (2) pp. E117-E126.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University